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a b s t r a c t
Angiotensin II is known to act primarily on the angiotensin AT1 receptors to mediate its
physiological and pathological actions. Des-aspartate-angiotensin I (DAA-I) is a bioactive
angiotensin peptide and have been shown to have contrasting vascular actions to angio-
tensin II. Previous work in this laboratory has demonstrated an overwhelming vasodepres-
sor modulation on angiotensin II-induced vasoconstriction by DAA-I. The present study
investigated the involvement of the AT1 receptor in the actions of DAA-I on angiotensin II-
induced vascular actions in the renal vasculature of normotensiveWistar–Kyoto rats (WKY),
spontaneously hypertensive rats (SHR) and streptozotocin (STZ)-induced diabetic rats. The
findings revealed that the angiotensin receptor in rat kidney homogenate wasmainly of the
AT1 subtype. The AT1 receptor density was significantly higher in the kidney of the SHR. The
increase in AT1 receptor densitywas also confirmed by RT-PCR andWestern blot analysis. In
contrast, AT1 receptor density was significantly reduced in the kidney of the streptozotocin-
induced diabetic rat. Perfusion with 109 M DAA-I reduced the AT1 receptor density in the
kidneys of WKY and SHR rats suggesting that the previously observed vasodepressor
modulation of the nonapeptide could be due to down-regulation or internalization of
AT1 receptors. RT-PCR and Western blot analysis showed no significant changes in the
content of AT1 receptor mRNA and protein. This supports the suggestion that DAA-I causes
internalization of AT1 receptors. In the streptozotocin-induced diabetic rat, no significant
changes in renal AT1 receptor density and expression were seen when its kidneys were
similarly perfused with DAA-I.
# 2008 Elsevier Inc. All rights reserved.
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The RAS plays an important role in the regulation of blood
pressure and fluid homeostatis and exerts this effect through
the production of angiotensin II. Angiotensin II increases the
renal vascular resistance by constricting afferent and efferent* Corresponding author. Fax: +60 3 79674791.
E-mail address: rais@um.edu.my (M.R. Mustafa).
0196-9781/$ – see front matter # 2008 Elsevier Inc. All rights reserved
doi:10.1016/j.peptides.2008.05.017arterioles including interlobular arteries [6]. The effects of
angiotensin II are mediated through high-affinity membrane
bound receptors, classified as AT1 and AT2 receptor subtypes.
Most of the known effects of angiotensin II have been
attributed to the AT1 receptor. In the kidney, AT1 receptors
are present in the preglomerular arteries and arterioles,.
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addition, angiotensin II plays a key role in the initiation and
amplification of pathobiological events that underlie several
vascular diseases. The findings of other bioactive angiotensin
peptides, i.e., DAA-I and angiotensin-(1–7) with contrasting
vascular actions to angiotensin II has generated interest in the
pleiotropism of the AT1 receptor and other receptor subtypes
that mediate their actions.
Angiotensin peptides may bind to multiple angiotensin
receptor subtypes that often exhibit different and sometimes
opposing actions. For example, angiotensin II has been shown
to bind to bothAT1 andAT2 receptor subtypewhich are coupled
to specific effector systems that elicit different biological
responses. DAA-I, has been shown to have cardioprotective
action by modulating the expression the AT1 and AT2 receptor
differentially to attenuate cardiac hypertrophy in rats with
abdominal aortic coarctation [9]. This nonapeptide has also
been demonstrated to prevent myocardial infact expansion
through suppression of inflammatory cytokines and immune
cell infiltration [1]. Studies with rabbit [31] and rat aortic rings
[19], and rabbit pulmonary artery [30] demonstrated that DAA-I
acts as an agonist on losartan-sensitive angiotensin receptor.
In a recent study, we observed increased contractile
responses to angiotensin II in the kidney of SHR rats and
decreased responses in the kidney of STZ-induced diabetic rat,
and suggested that the differences could be due to changes in
the angiotensin receptor density [13]. We also demonstrated
that DAA-I had a vasodepressing action on the contractile
action of angiotensin II in theWKY and SHR renal vasculature
and ruled out the involvement of AT2 receptor in mediating
the observed responses [13]. As an extension of the earlier
investigation, the present study investigated the effect of
DAA-I on the profile of renal AT1 receptors in the WKY, SHR
and STZ-induced diabetic rats.2. Methodology
2.1. Animals
Male Wistar–Kyoto (WKY) rats and spontaneously hyperten-
sive rats (SHRs) weighing 250–300 g (11–12 weeks) were
obtained from Animal House in the University of Malaya
Medical Centre. The animals were fed standard rat chow and
tap water ad libitum.
2.2. Induction of diabetes
WKY was made diabetic by administration of streptozotocin
(STZ) 75 mg/kg intraperitoneally. Age matched controls
received equal volume of vehicle. Prior to injection, animal
weights and blood glucose levels were recorded. Body weights
and blood glucose were taken every 2 weeks until the 8th
week. Animals were considered diabetic if their blood glucose
concentration was >17 mM.
In our earlier part of the work [13], DAA-I was perfused
through the kidney and the possibility was considered that
this peptide acted on the angiotensin receptors present on the
membrane of any part of the whole kidney. Thus, we used the
whole kidney in the current study.2.3. Receptor binding assay
The right kidney from WKY, SHR and STZ-induced diabetic
ratswere isolated andperfusedwithKrebs solution containing
only captopril (30 mM) (control) or captopril and DAA-I (109 M
to 1015 M) for 90 min prior to its use for the preparation of
kidney membranes. At these concentrations, DAA-I was
effective in attenuating the contraction of kidney vasculature
induced by angiotensin II [13]. Kidney membrane was
prepared as described by Brown et al. [5] with slight
modification. Briefly, each kidney was minced into small
pieces and suspended 1:10 (w/v) in Tris–HCl buffer (50 mM, pH
7.4), homogenized and the homogenate was centrifuged at
30,000  g at 4 8C for 40 min. The resultant pellet was
resuspended and recentrifuged twice under the same condi-
tions. The final pellet was resuspended in Tris–HCl (20 mM, pH
7.4), containing NaCl (135 mM), KCl (10 mM), glucose (5 mM)
and MgCl2 (10 mM). Protein concentration was determined
using the Biuret assay. The preparedmembranes were kept as
aliquots at 80 8C for not longer than 3 months.
The displacement radioligand binding experiment was
carried out using the homologous competitive bindingmethod
described by Brown et al. [5] with slight modification. Each
aliquot of membrane suspension equivalent to 40 mg of
protein was added to a solution of 125I-Sar1–Ile8-Ang II (2.3–
2.5 104 c.p.m.) together with a different (increasing) concen-
tration of non-radioactive Sar1–Ile8-Ang II (0.0001–300 nM) in
300 ml of 50 mM Tris–HCl buffer (pH 7.4) containing 0.3 mM
phenylmethylsulphonyl fluoride (PMSF), 0.1 mM bacitracin
and 0.2% bovine serum albumin (BSA). The assaymixture was
incubated at 22 8C for 2 h with continuous shaking. The bound
and unbound ligand was separated by addition of cold bovine
gamma globulin and polyethylene glycol and centrifugation at
5000  g and 4 8C for 40 min. The radioactivity trapped in the
pellets was counted using a gamma counter (Wizard Gamma
Counter, PerkinElmer). Efficiency of the counter was 95%.
Receptor density was calculated using Graph Pad Prism
software. The assay was conducted in duplicate and repeated
three to four times per group.
2.4. Semi-quantitative reverse-transcriptase polymerase
chain reaction (RT-PCR)
The right kidneys from WKY, SHR and STZ-induced diabetic
rats were isolated and perfused with Krebs and captopril
(30 mM) (control) or with DAA-I (109 M to 1015 M) for 90 min.
The kidneys were frozen in liquid nitrogen and kept at 80 8C
for further RNA isolation. Total RNA was isolated from the
kidneys using Reagent1 system according to the manufac-
turer’s instructions. The tissue (100 mg) was homogenized in
the provided denaturing solution. Two molar sodium acetate
(pH 4) was then added, followed by phenol:chloroform:isamyl
alcohol. This mixture was then kept in ice for 15 min before
centrifuging at 10,000  g for 20 min at 4 8C. After centrifuga-
tion, the top aqueous phase containing the RNA was carefully
removed and equal volume of isopropanol was added to the
aqueous phase and incubated at 20 8C to allow precipitation
of RNA. The RNA was pelleted by ultracentrifugation and was
washed in ice-cold 75% ethanol, re-pelleted and dissolved in
nuclease-free water. The amount of RNA was quantified by
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months.
cDNA was synthesized using RevertaidTM H Minus First
Strand cDNA Synthesis Kit, according to the manufacturer’s
protocols. One microlitre of 0.5 mg/ml oligo (dT)18 primer was
added to 1 mg of total RNA. The final total volume was 12 ml.
The mixture was mixed gently, spun down and incubated at
70 8C for 5 min. Then, 4 ml of 5 reaction buffer, 1 ml of
RiboLockTM Ribonuclease inhibitor (20 U/ml), and 2 ml of 10 mM
dNTP mix were added to the mixture and spun down. The
mixture was incubated at 37 8C for 5 min. Lastly, 1 ml of
RevertAidTM H Minus M-MuLV reverse trancriptase was
added and the mixture incubated at 42 8C for 60 min. The
reaction was stopped by heating at 70 8C for 10 min. The
synthesized cDNA was kept at 20 8C.
One microlitre of synthesized cDNA was added to the
reaction mixture containing reaction buffer, 0.2 mM of each of
the two primers, 2 mMMgCl2, 0.2 mM of each dNTP and 1.25 U
of Taq polymerase. The final volume was 25 ml. The mixture
was spun down and placed in the thermal cycler (PTC-200, MJ
Research). After denaturation at 95 8C for 15 min, amplifica-
tion cycles of 94 8C, 60 8C and 72 8C for 30 s were performed.
Final elongationwas carried out at 72 8C for 2 min. GADPHwas
chosen as the internal standard. The PCR products were
electrophoresed using 1.5% agarose gel containing ethidium
bromide 0.5 mg/ml. The gel was subjected to ultraviolet light,
photographed (Kodak Digital Science) and analyzed.Primer (50–30) PCR
cycleSize
(bp)AT1 Fwd: ATCTCGCCTTGGCTGACTTA;
Rvs: GACTTCATTGGGTGGACGA35 200GADPH Fwd: GGTGCTGAGTATGTCGTG;
Rvs: TTCAGCTCTGGGATGACC35 400Fig. 1 – Displacement of 125I-Sar1–Ile8-Ang II by losartan
(&), Sar–Ile-Ang II (~) and PD123319 (!) in kidney
membrane preparations of untreated rats (control).List of primers used in semi-quantitative RT-PCR.
2.5. Western blotting
The right kidneys from WKY, SHR and STZ-induced diabetic
rats were isolated and perfused with Krebs and captopril
(30 mM) (control) or with DAA-I (109 M to 1015 M) for 90 min
prior to the homogenate preparation. Tissue homogenate was
prepared according to the method described by Zelezna et al.
[36] with slight modification. Kidneys were homogenized in
phosphate-buffered saline (PBS) containing protease inhibi-
tors (30 mg PMSF, 300 mg EDTA, and 0.5 mg bacitracin/ml).
Homogenates were centrifuged at 20,000  g for 10 min, and
pellets were re-suspended in PBS with protease inhibitors and
rinsed twice by centrifugation. Final pellet were re-suspended
and protein concentration were determined using Biuret
assay. The supernatant was heated to 95 8C for 5 min in the
presence of 2 treatment buffer (0.125 M Tris–HCl, 4% SDS,
20% glycerol, 0.2 M DTT, 0.02% Bromophenol blue, pH 6.8).
The protein (80 mg) was resolved on a 12.5% SDS-PAGE and
transferred to polyvinylidene difluoride (PVDF) membrane.
The blotted PVDFmembrane was saturated with 3% gelatin in
PBS, pH 7.4 containing 0.1% Tween-20 for 1 h at room
temperature to block non-specific binding. The membrane
was then sequentially incubated with AT1 receptor antibody
(Santa Cruz Biotechnology, 1:1100) overnight at 4 8C, washedwith Tris-buffered saline containing 0.1% Tween-20 and
followed by incubation with goat anti-rabbit IgG–HRP con-
jugated (1:1300) for 2 h at room temperature. After thorough
washing, the blot was developed by incubating with HRP-
complex until the bands have adequate intensity. The blotwas
dried, scanned and analyzed.
2.6. Statistical analysis
Data were expressed as mean  S.E.M. One-way ANOVA and
Dunnett post hoc test were employed to determine the
significance differences, with an accepted level of signifi-
cance of p < 0.05. Bmax and Kd value for receptor binding were
determined using the homologous competitive equation
(GraphPad Prism). The band intensities for RT-PCR and
Western blot weremeasured using a software package (Scion
image). The signals for RT-PCR were expressed relative to the
intensity of the GADPH amplicon for each co-amplified
sample.3. Results
3.1. Receptor binding assay
The binding of 125I-Sar1–Ile8-Ang II to the rat kidney mem-
branes was displaced by losartan and Sar1–Ile8-Ang II in a
concentration-dependent manner with an almost 100% dis-
placement at 107 M concentration (Fig. 1). On the other hand,
PD 123319, an AT2 receptor antagonist, displaced less than 30%
of the labelled ligand at 106 M. This shows that the kidney
membranes contain mainly AT1 receptors and a very small
proportion of AT2 receptors. Renal AT1 receptor density was
significantly higher in SHR (739.6  44.0 fmol/mg) and lower in
STZ-induced diabetic (271.5  34.94 fmol/mg) compared to
WKY (430.0  8.12 fmol/mg) (Fig. 2). AT1 binding affinity (Kd)
between WKY, SHR and STZ-induced diabetic rats were not
significantly different (Table 1).
In functional studies reported earlier [13], the involvement
of AT2 receptor in the vasomodulatory role of DAA-I was
excluded. Thus, subsequent experiments were focused on
Fig. 2 – Maximal binding capacity of [125I]-Sar1–Ile8-Ang II
(Bmax) in kidney membranes of WKY-, SHR- and STZ-
treated rats. Bars represent the mean valueW S.E.M. of at
least four experiments performed in duplicates. *Indicates
significant difference from WKY (p < 0.05).
Fig. 3 – AT1 receptor density in kidney of WKY (A), SHR (B)
and STZ-induced diabetic rats (C) pre-treated with DAA-I,
respectively. The bars represent the mean valueW S.E.M.
of four to five experiments. Empty bar represent control
groups and the shaded bars represents groups treated
with graded concentrations (10S9 M, 10S12 M and 10S15 M)
of DAA-I. *Indicates significant difference from respective
control group (p < 0.05).
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with 109 M DAA-I caused a significant reduction in renal AT1
receptor density in WKY and SHR rats (Fig. 3). DAA-I does not
affect the receptor density of AT1 receptor in the STZ-induced
diabetic rat kidney (Fig. 3). DAA-I did not affect the Kd of AT1
receptor for the iodinated ligand in renal membranes of the
three different groups of rats (Table 1).
3.2. RT-PCR
ThemRNA expression of AT1 receptors in the kidneys ofWKY,
SHR and STZ-induced diabetic rats is shown in Fig. 4. GADPH
was used as an internal standard. The densitometic values of
the AT1 receptor were normalized against the corresponding
GADPH values. Compared to the WKY, there was an increase
in renal AT1 receptor mRNA in the SHR (1.051  0.066 vs.
0.794  0.067, SHR and WKY, respectively) and a decrease in
the STZ-induced diabetic rats (0.592  0.052 vs. 0.794  0.067,Table 1 – Homologous competitive binding parameters
Groups Kd value (nM)
WKY 1.187  0.068
DAA-I (109 M) 0.889  0.092
DAA-I (1012 M) 1.012  0.152
DAA-I (1015 M) 1.465  0.182
SHR 1.440  0.125
DAA-I (109 M) 1.284  0.140
DAA-I (1012 M) 1.680  0.136
DAA-I (1015 M) 1.638  0.143
STZ-induced diabetic 0.784  0.229
DAA-I (109 M) 0.931  0.194
DAA-I (1012 M) 0.864  0.196
DAA-I (1015 M) 1.315  0.277
Values are expressed as mean  S.E.M. of 3–4 binding experiments.
Bmax values are in fmol/mg protein; Kd values are in nM.STZ-induced diabetic and WKY, respectively). The effects of
DAA-I (109 M to 1015 M) on the renal AT1 mRNA expression
are shown in Fig. 5. DAA-I did not significantly alter the level of
AT1 mRNA in the kidney of WKY, SHR and STZ-induced
diabetic rats.
3.3. Western blotting
The AT1 receptor antibody has a molecular weight of 43 kDa.
The expression of AT1 receptor protein in the kidney of WKY,
SHR and STZ-induced diabetic rats is shown in Fig. 6.
Compared to the WKY, there was an increase in AT1 receptor
protein in the SHR and a decrease in the STZ-induced diabetic
rats. The effects of DAA-I (109 M to 1015 M) on the expression
of AT1 receptor protein in the kidney of WKY, SHR and STZ-
induced diabetic rats are shown in Fig. 7. Ninety minutes of
perfusionwith DAA-I perfusion did not affect the AT1 receptor
Fig. 4 – AT1 mRNA expression level in the kidney of WKY,
SHR and STZ-induced diabetic rats: (A) agarose gel
electropherogram of AT1 and GAPDH cDNA; (B)
quantification of AT1 mRNA (normalized against GADPH
mRNA). The bars represent the meanW S.E.M. of three to
four rats. *Indicates significant difference from the WKY
value (p < 0.05).
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diabetic rats.4. Discussion
4.1. Profile of renal angiotensin receptor
In the present study, homologous competitive binding assay
performed with specific AT1 receptor antagonist, losartan and
the AT2 receptor antagonist, PD123319 revealed that the AT1
receptorwas themain angiotensin receptor subtype present in
the kidney membrane. Several binding studies have also
shown exclusive presence of AT1 receptors in the renal
glomeruli, tubular and outer medullary membranes of
Sprague–Dawley rats [14,15]. Autoradiographic techniques
have also localized a predominant expression of AT1 receptor
in the adult rat kidneys [11]. RT-PCR andWestern blot analysis
have additionally showed a predominance of AT1 receptor
localization in the rat kidneys [21,24,36].
The binding study also shows that AT1 receptor density
was significantly higher in the SHR compared to theWKY rats.
The finding supports those of earlier investigators [5,16,17].
These authors have correlated the increase in AT1 receptor to
the enhancement of angiotensin II-induced renal contractility.
The receptor affinity (Kd) for the AT1 receptor remained
unchanged in the WKY and SHR animals. The lack of
alteration in AT1 receptor affinity in hypertensive animals
have also been reported by other authors [7,17]. RT-PCR and
Western blot analysis are in agreement with the result fromthe receptor binding assay. Increases in AT1 receptor mRNA
have been observed in the brain [25,26], aorta [23] and heart of
the SHR [20], and glomeruli of stroke-prone SHR [22].
In contrast, the AT1 receptor density in the kidney of STZ-
treated rats was significantly lower when compared to the
density present in the WKY. This reduction mirrors the
reduced responsiveness to angiotensin II observed in the
perfused kidney in our previous work [13]. Reduction in AT1
receptor density was similarly demonstrated in whole kidney
homogenates [5] and glomerulus [2,3,35] of STZ-induced
diabetic rats. No significant differences in AT1 receptor affinity
was observed between WKY and STZ-treated rats. Similar
observations were also documented by other researchers [2,3].
RT-PCR results andWestern blot analysis are in agreement the
binding data and with our earlier work where a lower AT1
mRNA level was observed in the kidney of STZ-induced
diabetic rats. Reduced renal expression of the AT1 receptor has
been reported in renal proximal tubules [10] of diabetic SHR
animals [4] and diabetic patients [33]. However, a study by
Sharma et al. [29] found that kidneys from diabetic rats exhibit
decreased expression of the type I inositol triphosphatase
receptor (InsP3R) isoform and speculated that the impaired
angiotensin II-mediated vasoconstriction in diabetic animals
might be caused by down-regulation of InsP3Rs. In a later
study, this author showed that AT1 receptor mRNA remains
unchanged in aorta from STZ-induced diabetic rats [28]. In
contrast, Wehbi et al. [34] showed no significant change of the
AT1 receptor but reduced AT2 receptor expression in the
kidney of diabetic rats. The different profiles of the angio-
tensin AT1 receptors seen in diabetic animals reflect the
complex metabolic disorder of the disease. In addition, such
differences could also be due to the different animal strains
and the period used to induce diabetes.
4.2. Effect of DAA-I on renal AT1 receptor
Perfusion of the kidney with 109 M DAA-I significantly
reduces AT1 receptor density in both the WKY and SHR
kidney membranes. This suggests that the vasodepressor
actions of DAA-I may in part be due to a down-regulation of
the AT1 receptor in the kidney of WKY and SHR rats. Changes
in receptor protein synthesis have been identified as late
signalling events, and take hours to occur [32]. As DAA-I was
perfused into the kidneys for more than 1 h; it is possible that
an adequate concentration of the nonapeptide could down-
regulate the AT1 receptors. However, the RT-PCR andWestern
blot analysis did not showdown-regulation of AT1 receptors as
there were no changes in gene and protein expression with
pre-treatment of 109 M DAA-I concentration. It is possible
that the reducedAT1 receptor density observed at 10
9 MDAA-
I may be due to receptor internalization.
Receptor internalization leads to a reduction in the number
of receptors present on the membrane surface [27]. This may
explain the findings from our binding assay as DAA-I may
have repositioned the AT1 receptor into the membrane and
lysis of the membrane for Western blot may have exposed the
internalized receptors. Agonist-induced receptor internaliza-
tion especially of AT1 receptor has been reported [12,18].
Studies on endogenous AT2 receptors have demonstrated that
it is an internalization-deficient receptor [18]. Internalization
Fig. 5 – Effect of DAA-I on the expression of AT1 mRNA in perfused kidney of WKY (A), SHR (B) and STZ-induced diabetic rats
(C). Above each bar chart is the respective agarose gel electropherogram of AT1 and GADPH cDNA. The bars represent the
mean valueW S.E.M. of four to five experiments. Empty bars represent control groups and the shaded bars represent groups
treated with graded concentrations (10S9 M, 10S12 M and 10S15 M) of DAA-I. Each bar is expressed as a percentage of the
control. *Indicates significant difference from respective control group (p < 0.05).
Fig. 6 – AT1 receptor expression levels in the kidney of
WKY, SHR and STZ-induced diabetic rats: (A) Western blot
of AT1 receptor; (B) densitometric quantification of AT1
receptor level. The bars represent the mean W S.E.M. of
three rats. *Indicates significant difference from the WKY
value (p < 0.05).
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observed earlier in the isolated perfused kidneys of WKY and
SHR animals.
Pre-treatment with 1012 M and 1015 M DAA-I did not
affect the AT1 receptor density although reduction in
contractility was observed in the ex vivo renal study [13]. A
slight reduction in receptor density was seen in 1012 M pre-
treated kidneys especially in the SHR. A similar pattern was
also observedwith RT-PCR andWestern blot analysis. At these
subphysiological concentrations, a small difference in recep-
tor availability could still contribute to the observed attenua-
tion of angiotensin II contraction. It is also possible that DAA-I
binds to the AT1 receptor and activate different second
messenger pathways, which contributed to its vasodepressor
actions. In such a scenario, internalization of theAT1 receptors
is a normal negative feedback mechanism occurring at
concentrations above paraphysiological level and absent at
lower concentrations.
Pre-treatment with DAA-I did not affect the renal AT1
receptor density in STZ-treated kidney. This perhaps explains
our earlier result, where DAA-I had no effect on angiotensin II-
induced vasoconstriction in STZ-induced diabetic rat kidney
[13]. The actual underlying mechanisms for this absence of
Fig. 7 – Effect of DAA-I on the expression of AT1 receptor levels in perfused kidney of WKY (A), SHR (B) and STZ-induced
diabetic rats (C). Above each bar is the respective blot for AT1 receptor. Empty bars represent control groups and the shaded
bars represent groups treated with graded concentrations (10S9 M, 10S12 M and 10S15 M) of DAA-I. Each bar represents the
meanW S.E.M. of three rats and expressed over its control. *Indicates significantly different from its control value (p < 0.05).
p e p t i d e s 2 9 ( 2 0 0 8 ) 1 7 7 3 – 1 7 8 0 1779effects are not known. In agreementwith the binding assay, no
changes in AT1 receptor gene and protein expressionwas seen
in the STZ-induced diabetic rat kidney. As structural changes
occur during the diabetes, it is possible that the binding site
for DAA-I at AT1 receptor may be altered, thus reducing the
ability of DAA-I to bind to AT1 receptor. A slightly lower AT1
receptor affinity was detected in the STZ-induced diabetic
untreated and DAA-I treated animals compared to the WKY.
No significant difference in receptor affinity was observed
between the DAA-I treated group with its own control further
suggests that the DAA-I binds to other binding site than Ang II
to modulate the AT1 receptors.
In summary, the present finding demonstrated the accom-
panying changes in AT1 receptor profile following effective
vasomodulatoryconcentrationsofDAA-I in thekidneysofWKY
and SHR. The data support the contention that DAA-I acts via
theAT1 receptor in that it internalizes the receptors in these two
animal strains and not in the STZ-induced diabetic rats where
DAA-I has no vasodepressor action.r e f e r e n c e s[1] Abd Jalil R, Haider HK, Sim MK, Ding PZ, Ramos LB, Jiang S,
et al. Cardioprotective effect of des-aspartate-angiotensin I
(DAA-I) on cytokine gene expression profile in ligation of
model of myocardial infarction. Life Sci 2006;78:341–51.[2] Amiri F, Garcia R. Renal angiotensin II receptors and protein
kinase C in diabetic rats: effects of insulin and ACE
inhibition. Am J Physiol Renal Physiol 2000;278:F603–12.
[3] Ballermann BJ, Skorecki KL, Brenner BM. Reduced
glomerular angiotensin II receptor density in early
untreated diabetes mellitus in the rat. Am J Physiol
1984;247:F110–6.
[4] Bonnet F, Candido R, Carey RM, Casley D, Russo LM, Osicka
TM, et al. Renal expression of angiotensin receptors in long
term diabetes and the effects of angiotensin 1 receptor
blockade. J Hypertens 2002;20:1615–24.
[5] Brown L, Wall D, Marchant C, Sernia C. Tissue-specific
changes in angiotensin II receptors in streptozotocin-
diabetic rats. J Endocrinol 1997;154:355–62.
[6] Carmines PK, Morrison TK, Navar LG. Angiotensin II effects
on microvascular diameters of in vitro blood-perfused
juxtamedullary nephrons. Am J Physiol 1986;251:F610–8.
[7] Chatziantoniou C, Arendshorst WJ. Angiotensin and
thromboxane in genetically hypertensive rats: renal
blood flow and receptor studies. Am J Physiol 1991;261:
F238–47.
[8] Chatziantoniou C, Arendshorst WJ. Angiotensin receptor
sites in renal vasculature of rats developing genetic
hypertension. Am J Physiol 1993;265:F853–62.
[9] Chen WS, Sim MK. Effects of des-Asp-angiotensin I on the
expression of AT1 and AT2 receptors in ventricles of
hypertrophic rat hearts. Regul Pept 2004;117:207–12.
[10] Cheng HF, Burns KD, Harris RC. Reduced proximal tubule
angiotensin II receptor expression in streptozotocin-
induced diabetes mellitus. Kidney Int 1994;46:1603–10.
[11] Ciuffo GM, Viswanathan M, Selter AM, Tsutsumi K,
Saavedra JM. Glomerular angiotensin II receptor subtypes
p e p t i d e s 2 9 ( 2 0 0 8 ) 1 7 7 3 – 1 7 8 01780during development of rat kidney. Am J Physiol
1993;265:F264–71.
[12] Conchon S, Monnot C, Teutsch B, Corvol P, Clauser E.
Internalization of the rat AT1a and AT1b receptors:
pharmacological and functional requirements. FEBS Lett
1994;349:365–70.
[13] Dharmani M, Mustafa MR, Achike FI, Sim MK. Effects of
des-Asp-angiotensin I on the action of angiotensin II in
isolated renal and mesenteric vasculature of normo- and
hypertensive and STZ-induced diabetic rats. Regul Pept
2005;129:213–9.
[14] Edwards RM, Aiyar N. Angiotensin II receptor subtypes in
the kidney. J Am Soc Nephrol 1993;3:1643–52.
[15] Gauquelin G, Garcia R. Characterization of glomerular
angiotensin II receptor subtypes. Receptor 1992;2:
207–12.
[16] Gutkind JS, Kurihara M, Castren E, Saavedra JM. Increased
concentration of angiotensin II binding sites in selected
brain areas of spontaneously hypertensive rats. J Hypertens
1988;6:79–84.
[17] Haddad G, Garcia R. Characterization and hemodynamic
implications of renal vascular angiotensin II receptors in
SHR. J Mol Cell Cardiol 1996;28:351–61.
[18] Hunyady L, Catt KJ, Clark AJ, Gaborik Z. Mechanisms and
functions of AT(1) angiotensin receptor internalization.
Regul Pept 2000;91:29–44.
[19] Lim BC, Sim MK. Actions of des-Asp angiotensin I on the
aortic rings of the normo- and hypertensive rats. Clin Exp
Hypertens 1998;20:105–17.
[20] Makino N, Sugano M, Otsuka S, Hata T. Molecular
mechanism of angiotensin II type 1 and type 2 receptors in
cardiac hypertrophy of spontaneously hypertensive rats.
Hypertension 1997;30:796–802.
[21] Miyata N, Park F, Li XF, Cowley Jr AW. Distribution of
angiotensin AT1 and AT2 receptor subtypes in the rat
kidney. Am J Physiol 1999;277:F437–46.
[22] Obata J, Nakamura T, Takano H, Naito A, Kimura H,
Yoshida Y, et al. Increased gene expression of components
of the renin-angiotensin system in glomeruli of genetically
hypertensive rats. J Hypertens 2000;18:1247–55.
[23] Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y.
Interaction of mRNAs for angiotensin II type 1 and type 2
receptors to vascular remodelling in spontaneously
hypertensive rats. Hypertension 1998;32:467–72.
[24] Paxton WG, Runge M, Horaist C, Cohen C, Alexander RW,
Bernstein KE. Immunohistochemical localization of ratangiotensin II AT1 receptor. Am J Physiol 1993;264:
F989–95.
[25] Raizada MK, Sumners C, Lu D. Angiotensin II type 1
receptor mRNA levels in the brains of normotensive and
spontaneously hypertensive rats. J Neurochem
1993;60:1949–52.
[26] Reja V, Goodchild AK, Phillips JK, Pilowsky PM.
Upregulation of AT1 receptor and intracellular kinase gene
expression in hypertensive rats. Clin Exp Pharmacol
Physiol 2006;33:690–5.
[27] Sasamura H, Dzau VJ, Pratt RE. Desensitisation of
angiotensin receptor function. Kidney Int 1994;46:1499–501.
[28] Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S,
et al. Involvement of transforming growth factor-beta in
regulation of calcium transients in diabetic vascular
smooth muscle cells. Am J Physiol Renal Physiol
2003;285:F1258–70.
[29] Sharma K, Wang L, Zhu Y, Deguzman A, Cao GY, Lynn RB,
et al. Renal type I inositol 1,4,5-triphosphate receptor is
reduced in streptozotocin-induced diabetic rat and mice.
Am J Physiol 1999;276:F54–61.
[30] Sim MK, Min L. Des-aspartate-angiotensin I and
angiotensin AT1 receptors in rat cardiac ventricles. Regul
Pept 2005;129:133–7.
[31] Sim MK, Yuan HT. Effects of des-Asp-angiotensin I on the
contractile action of angiotensin II and angiotensin III. Eur J
Pharmacol 1995;278:175–8.
[32] Touyz RM, Schiffrin EL. Signal transduction mechanisms
mediating the physiological and pathophysiological actions
of angiotensin II in vascular smooth muscle cells.
Pharmacol Rev 2000;52:639–72.
[33] Wagner J, Gehlen F, Ciechanowicz A, Ritz E. Angiotensin II
receptor type 1 gene expression in human
glomerulonephritis and diabetes mellitus. J Am Soc
Nephrol 1999;10:545–51.
[34] Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD.
Early streptozotocin diabetes mellitus downregulates rat
kidney AT2 receptors. Am J Physiol Renal Physiol
2001;280:F254–65.
[35] Wilkes BM. Reduced glomerular angiotensin II receptor
density in diabetes mellitus in the rat: time course and
mechanism. Endocrinology 1987;120:1291–8.
[36] Zelezna B, Richards EM, Tang W, Lu D, Sumners C, Raizada
MK. Characterization of a polyclonal anti-peptide antibody
to the angiotensin II type 1 (AT1) receptor. Biochem Biophys
Res Commun 1992;183:781–8.
